Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 4Active not recruiting 3Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Genitourinary 4Thoracic 3Other solid neoplasm 3Gastrointestinal 3Tumor-Agnostic 1NET 1Head & Neck 1Endocrine 1Breast 1

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2Oligometastatic Prostate Cancer 1Metastatic Urothelial Cancer 1Erythrocytosis, Familial, 4 1

Interventions

Magnetic Resonance Spectroscopy 86pembrolizumab 76Specimen Handling 75enzalutamide 55Radiosurgery 55Radiotherapy 51Docetaxel 50Androgen Antagonists 47Gemcitabine 42Nivolumab 39darolutamide 37Prednisone 35enfortumab vedotin 32Abiraterone Acetate 31Cisplatin 30Biopsy 30Carboplatin 29cabozantinib 28Standard of Care 28apalutamide 27Pluvicto 26abiraterone 25Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 22X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × zimberelimab × Genitourinary × Clear all
NCT05536141 2026-05-01

ARC-20

Arcus Biosciences, Inc.

Phase 1 Recruiting
362 enrolled
Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting
827 enrolled 1 FDA
Genitourinary

Metastatic Urothelial Cancer

NCT05915442 2025-05-20

SBRT-AMICO

Columbia University

Phase 2 Recruiting
23 enrolled
Genitourinary

Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡